A systematic review and economic model of the effectiveness and ...

235. Rhodes SM, Coghill DR, Matthews K.
Neuropsychological profile and response to
methylphenidate in girls with hyperkinetic
disorder (ADHD). J Psychopharmacol 2003;17 (3
Suppl):A73.
236. Riyad CE, Skowronsk iGA, Turkall RM, Abdel-
Rahman MS. A study of safety factors for risk
assessment of drugs used for treatment of
attention deficiency hyperactivity disorder in
sensitive populations. Hum Ecol Risk Assess
2002;8:823–40.
237. Rubia K, Noorloos J, Smith A, Gunning B,
Sergeant J. Motor timing deficits in community
and clinical boys with hyperactive behavior: the
effect of methylphenidate on motor timing.
J Abnorm Child Psychol 2003;31:301–13.
238. Schachter HM, Pham B, King J, Langford S,
Moher D. How efficacious and safe is short-acting
methylphenidate for the treatment of attentiondeficit
disorder in children and adolescents? A
meta-analysis. CMAJ 2001;165:1475–88.
239. Scheres A, Oosterlaan J, Swanson J, Morein-Zamir
S, Meiran N, Schut H, et al. The effect of
methylphenidate on three forms of response
inhibition in boys with AD/HD. J Abnorm Child
Psychol 2003;31:105–20.
240. Sharp WS, Walter JM, Marsh WL, Ritchie GF,
Hamburger SD, Castellanos FX. ADHD in girls:
clinical comparability of a research sample. In
Hertzig ME, Farber EA, editors. Annual progress in
child psychiatry and child development 2000–2001.
New York: Brunner Routledge; 2003. pp. 263–77.
241. Shaughnessy A. Does Adderall produce similar
results as methylphenidate in children with
attention deficit-hyperactivity disorder? Evid Based
Pract 1999;2:7.
242. Smith BH, Waschbusch DA, Willoughby MT, Evans
S. The efficacy, safety, and practicality of
treatments for adolescents with attentiondeficit/hyperactivity
disorder (ADHD). Clin Child
Fam Psychol Rev 2000;3:243–67.
243. Smith R, Larsen D, Derby KM, McLaughlin TF,
Weber KP, Brown K, et al. A comparison of teacher
checklists used over 15 days and a one-day
antecedent analysis to conduct a medication trial.
Psychol Schools 2004;41:235–40.
244. Spencer TJ. Atomoxetine treatment in children
with attention-deficit/hyperactivity disorder and
comorbid tic disorders. Biol Psychiatry 2004;55
(1S-242S):185.
245. Sunohara GA, Malone MA, Rovet J, Humphries T,
Roberts W, Taylor MJ. Effect of methylphenidate
on attention in children with attention deficit
hyperactivity disorder (ADHD): ERP evidence.
Neuropsychopharmacology 1999;21:218–28.
© Queen’s Printer and Controller of HMSO 2006. All rights reserved.
Health Technology Assessment 2006; Vol. 10: No. 23
246. Swanson JM, Wigal SB, Lemer MA. Comparison of
the efficacy and safety of OROS methylphenidate
HCl with methylphenidate tid and placebo in
children with ADHD. Pediatr Res 2000;47:34A.
247. Swanson JM. Evaluation of different
methylphenidate (MPH) delivery patterns for the
treatment of children with ADHD. Neurology
2000;54 (Suppl 7):A420.
248. Swanson J, Wigal S, Greenhill L, Browne R,
Waslick B, Lerner M, et al. Objective and subjective
measures of the pharmacodynamic effects of
Adderall ® in the treatment of children with ADHD
in a controlled laboratory classroom setting.
Psychopharmacol Bull 1998;34:55–60.
249. Swanson JM, Wigal S, Greenhill LL, Browne R,
Waslik B, Lerner M, et al. Analog classroom
assessment of Adderall ® in children with
ADHD. J Am Acad Child Adolesc Psychiatry 1998;
37:519–26.
250. Swanson JM, Gupta S, Williams L, Agler D,
Lerner M, Wigal S. Efficacy of a new pattern of
delivery of methylphenidate for the treatment of
ADHD: effects on activity level in the classroom
and on the playground. J Am Acad Child Adolesc
Psychiatry 2002;41:1306–14.
251. Swanson J, Gupta S, Guinta D, Flynn D, Agler D,
Lerner M, et al. Acute tolerance to
methylphenidate in the treatment of attention
deficit hyperactivity disorder in children. Clin
Pharmacol Ther 1999;66:295–305.
252. Swanson J, Sadeh A, Lerner MA, Wigal SB.
Comparison of the impact of OROS
methylphenidate HCI with methylphenidate tid
and placebo on the sleep of children with ADHD.
J Dev Behav Pediatr 2000;21:387–8.
253. Swanson J, Wigal S, Lerner M. Treatment with a
controlled-release formulation of methylphenidate
for attention-deficit/hyperactivity disorder: onset
and duration of effect. Eur Neuropsychopharmacol
2002;12 (Suppl 3):S414.
254. Szobot CM, Ketzer C, Cunha RD, Parente MA,
Langleben DD, Acton PD, et al. The acute effect of
methylphenidate on cerebral blood flow in boys
with attention-deficit/hyperactivity disorder. Eur J
Nucl Med Mol Imaging 2003;30:423–6.
255. Tenreiro K. Methylphenidate–placebo: a trial for
attention deficit disorders. International Journal of
Pharmaceutical Computing 2001;5:21–2.
256. The Tourette’s Syndrome Study Group. Treatment
of ADHD in children with tics: a randomized
controlled trial.comment. Neurology
2002;58:527–36.
257. Tillery KL, Katz J, Keller WD. Effects of
methylphenidate (Ritalan) on auditory
performance in children with attention and
auditory processing disorders. J Speech Lang Hear
Res 2000;43:893–901.
143